136 related articles for article (PubMed ID: 34656072)
1. Effect of the Proton Pump Inhibitor Esomeprazole on the Systemic Exposure of Capecitabine: Results of A Randomized Crossover Trial.
van Doorn L; Heersche N; de Man FM; de Bruijn P; Bijl I; Oomen-de Hoop E; Eskens FALM; van der Gaast A; Mathijssen RHJ; Bins S
Clin Pharmacol Ther; 2022 Feb; 111(2):455-460. PubMed ID: 34656072
[TBL] [Abstract][Full Text] [Related]
2. Influence of the Acidic Beverage Cola on the Absorption of Erlotinib in Patients With Non-Small-Cell Lung Cancer.
van Leeuwen RW; Peric R; Hussaarts KG; Kienhuis E; IJzerman NS; de Bruijn P; van der Leest C; Codrington H; Kloover JS; van der Holt B; Aerts JG; van Gelder T; Mathijssen RH
J Clin Oncol; 2016 Apr; 34(12):1309-14. PubMed ID: 26858332
[TBL] [Abstract][Full Text] [Related]
3. Rabeprazole intake does not affect systemic exposure to capecitabine and its metabolites, 5'-deoxy-5-fluorocytidine, 5'-deoxy-5-fluorouridine, and 5-fluorouracil.
Sekido M; Fujita KI; Kubota Y; Ishida H; Takahashi T; Ohkuma R; Tsunoda T; Ishikawa F; Shibanuma M; Sasaki Y
Cancer Chemother Pharmacol; 2019 Jun; 83(6):1127-1135. PubMed ID: 30972456
[TBL] [Abstract][Full Text] [Related]
4. Influence of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib: A Randomized Crossover Pharmacokinetic Study.
de Man FM; Hussaarts KGAM; de With M; Oomen-de Hoop E; de Bruijn P; van Halteren HK; van der Burg-de Graauw NCHP; Eskens FALM; van Gelder T; van Leeuwen RWF; Mathijssen RHJ
Clin Pharmacol Ther; 2019 Jun; 105(6):1456-1461. PubMed ID: 30570132
[TBL] [Abstract][Full Text] [Related]
5. The pharmacokinetics, pharmacodynamics and safety of oral doses of ilaprazole 10, 20 and 40 mg and esomeprazole 40 mg in healthy subjects: a randomised, open-label crossover study.
Shin JS; Lee JY; Cho KH; Park HL; Kukulka M; Wu JT; Kim DY; Park SH
Aliment Pharmacol Ther; 2014 Sep; 40(5):548-61. PubMed ID: 25041486
[TBL] [Abstract][Full Text] [Related]
6. Influence of esomeprazole on the bioavailability of afatinib: A pharmacokinetic cross-over study in patients with non-small cell lung cancer.
Veerman GDM; Hurkmans DP; Paats MS; Oomen-de Hoop E; van der Leest CH; van Thiel ERE; Aerts JGJV; van Leeuwen RW; Dingemans AC; Mathijssen RHJ
Biomed Pharmacother; 2022 Nov; 155():113695. PubMed ID: 36126454
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the pharmacokinetics and tolerability of HCP1004 (a fixed-dose combination of naproxen and esomeprazole strontium) and VIMOVO® (a marketed fixed-dose combination of naproxen and esomeprazole magnesium) in healthy volunteers.
Choi Y; Han H; Shin D; Lim KS; Yu KS
Drug Des Devel Ther; 2015; 9():4127-35. PubMed ID: 26257511
[TBL] [Abstract][Full Text] [Related]
8. Effect of pH and comedication on gastrointestinal absorption of posaconazole: monitoring of intraluminal and plasma drug concentrations.
Walravens J; Brouwers J; Spriet I; Tack J; Annaert P; Augustijns P
Clin Pharmacokinet; 2011 Nov; 50(11):725-34. PubMed ID: 21973269
[TBL] [Abstract][Full Text] [Related]
9. Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors.
Tan AR; Gibbon DG; Stein MN; Lindquist D; Edenfield JW; Martin JC; Gregory C; Suttle AB; Tada H; Botbyl J; Stephenson JJ
Cancer Chemother Pharmacol; 2013 Jun; 71(6):1635-43. PubMed ID: 23636448
[TBL] [Abstract][Full Text] [Related]
10. Oral esomeprazole in Japanese pediatric patients with gastric acid-related disease: Safety, efficacy, and pharmacokinetics.
Shimizu T; Nakayama Y; Ishii E; Ida S; Satou T; Tokuhara D; Arai K; Nii M; Rydholm H; Yajima T;
Pediatr Int; 2019 Jan; 61(1):87-95. PubMed ID: 30422368
[TBL] [Abstract][Full Text] [Related]
11. Effect of esomeprazole with/without acetylsalicylic acid, omeprazole and lansoprazole on pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers.
Andersson T; Nagy P; Niazi M; Nylander S; Galbraith H; Ranjan S; Wallentin L
Am J Cardiovasc Drugs; 2014 Jun; 14(3):217-27. PubMed ID: 24677117
[TBL] [Abstract][Full Text] [Related]
12. A phase 0 clinical trial of novel candidate extended-release formulations of capecitabine.
Jacobs BA; Meulenaar J; Rosing H; Pluim D; Tibben MM; de Vries N; Nuijen B; Huitema AD; Beijnen JH; Schellens JH; Marchetti S
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1201-7. PubMed ID: 27103124
[TBL] [Abstract][Full Text] [Related]
13. Assessment of drug-drug interaction potential between ceritinib and proton pump inhibitors in healthy subjects and in patients with ALK-positive non-small cell lung cancer.
Lau YY; Gu W; Lin T; Viraswami-Appanna K; Cai C; Scott JW; Shi M
Cancer Chemother Pharmacol; 2017 Jun; 79(6):1119-1128. PubMed ID: 28424965
[TBL] [Abstract][Full Text] [Related]
14. The effect of dose and type of proton pump inhibitor use on risk of fractures and osteoporosis treatment in older Australian women: A prospective cohort study.
van der Hoorn MMC; Tett SE; de Vries OJ; Dobson AJ; Peeters GMEEG
Bone; 2015 Dec; 81():675-682. PubMed ID: 26319499
[TBL] [Abstract][Full Text] [Related]
15. Intravenous esomeprazole for prevention of recurrent peptic ulcer bleeding: a randomized trial.
Sung JJ; Barkun A; Kuipers EJ; Mössner J; Jensen DM; Stuart R; Lau JY; Ahlbom H; Kilhamn J; Lind T;
Ann Intern Med; 2009 Apr; 150(7):455-64. PubMed ID: 19221370
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and relative bioavailability of a fixed-dose combination of enteric-coated naproxen and non-enteric-coated esomeprazole magnesium.
Wang-Smith L; Fort J; Zhang Y; Sostek M
J Clin Pharmacol; 2012 May; 52(5):670-80. PubMed ID: 21628602
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the pharmacokinetics of trazpiroben (TAK-906) in the presence and absence of the proton pump inhibitor esomeprazole.
Kaur Mukker J; Dukes G; Wang L; Huh S; Khudyakov P; Nishihara M; Chen C
Clin Transl Sci; 2022 May; 15(5):1281-1290. PubMed ID: 35218604
[TBL] [Abstract][Full Text] [Related]
18. Effect of esomeprazole, a proton pump inhibitor on the pharmacokinetics of sonidegib in healthy volunteers.
Zhou J; Quinlan M; Glenn K; Boss H; Picard F; Castro H; Sellami D
Br J Clin Pharmacol; 2016 Oct; 82(4):1022-9. PubMed ID: 27277189
[TBL] [Abstract][Full Text] [Related]
19. Influence of Cow's Milk and Esomeprazole on the Absorption of Erlotinib: A Randomized, Crossover Pharmacokinetic Study in Lung Cancer Patients.
Veerman GDM; Hussaarts KGAM; Peric R; Oomen-de Hoop E; Landa KD; van der Leest CH; Broerse SD; Rutten HB; Belderbos HNA; Steendam CMJ; Paats MS; Koolen SLW; Dingemans AC; van Gelder T; van Leeuwen RWF; Aerts JGJV; Mathijssen RHJ
Clin Pharmacokinet; 2021 Jan; 60(1):69-77. PubMed ID: 32557346
[TBL] [Abstract][Full Text] [Related]
20. Comparative Pharmacokinetics/Pharmacodynamics of Fixed-Dose Combination of Esomeprazole and Calcium Carbonate (AD-206) to the Conventional Esomeprazole.
Bae S; Kwon J; Lee SB; Jang IJ; Yu KS; Lee S
Drug Des Devel Ther; 2021; 15():5099-5108. PubMed ID: 34992346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
